Clinical Trial Update: Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of celecoxib and erlotinib in former smokers with stage IIIB or stage IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED